Cool lion concept, real photo
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Liontown (ASX:LTR) has confirmed its first spodumene concentrate shipment will leave Kathleen Valley later this month within the same window the company has hit a production milestone of 10,000tn.

The question now remains what price can the company snag for it, and, will it be enough to keep Liontown going through a lithium downturn.

The company’s processing plant continues to be the subject of upgrades, now supporting a stockpile build where the average concentrate grade is 5.2% lithium oxide. This lines up with LTR’s expectations, it reported.

A storage facility, road transport logistics and a port shed are now all in play for Liontown in advance of its first shipment before the start of October.

Of course, the fact is that lithium prices are unlikely to hit their 2022 highs again any time soon. Shareholders in Liontown might not get the same uplift that Pilbara Minerals’ saw when it began to export spodumene in its hotly anticipated BWX auctions not that long ago.

All in all, the lithium price boom in the early 2020’s was never really about EV demand – it was largely just another COVID-borne supply chain shortage story. A tough reality, but a sound one.

“The successful mobilisation of our logistics chain and the operational readiness of our site facilities underscores our strong commitment to delivering on our commitments,” LTR CEO Tony Ottaviano said.

“As we eagerly anticipate our first shipment, scheduled for September, this progress positions us on the cusp of revenue generation, reinforcing our dedication to enhancing shareholder value.”

Liontown’s resilience through the last two years could be the bigger story.

LTR last traded at 65cps.

ltr by the numbers
More From The Market Online

KGL Resources jumps 25% on US$300M funding deal

KGL Resources has entered into a US$300 million PMPA to help fund construction and development of…
London

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment

Terra hits multiple intersections at Southwest SW6 prospect; assays now due in next ~12 weeks

Terra Metals has hit multiple intersections of massive sulphides in drilling at the Southwest SW6 prospect…
Easter bunny in a business suit analyzing stock charts, symbolizing market strategy

ASX closed for Easter long weekend. Enjoy your chocolates and the holiday break!

Yes, yes, I know you’re itching to do some serious Australian market trading today, but everyone — especially our much-loved HotCopper forum users